You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

The ‘Jekyll and Hyde’ of atherosclerosis

By Dermot - 22nd Oct 2020 | 19 views

Cropped shot of an unrecognizable senior male holding his chest while sitting indoors

Irish Cardiac Society, 71st Annual Scientific Meeting, 1-3 October 2020

In a session chaired by Dr Ian Menown, Consultant Cardiologist and Director of Invasive Cardiology at the Craigavon Cardiac Centre, Co Armagh, attendees at the conference heard a presentation from Prof Alberto Zambon, Director at the Lipoprotein Core Laboratory, Centre for Atherosclerosis Prevention and Treatment, Department of Medicine, University of Padua, Italy. Prof Zambon spoke on the topic of ‘Triglycerides in Atherosclerosis: A Strange Case of Dr Jekyll and Mr Hyde’.

“It’s a strange story, because if we look at lipoproteins, we have a clear idea of the lipoproteins that are dangerous for our arteries,” said Prof Zambon. “But then we have a range of proteins where we are not exactly sure what they do – are they bad or good, do they do anything or do something?” In his presentation, Prof Zambon focused on the mild-to-moderate range of triglycerides in the range of 2-to-10mmol/L not associated with increased risk of pancreatitis, but with an increased risk of cardiovascular disease.

Prof Alberto Zambon

“Triglycerides might not be dangerous, but the cholesterol in the triglyceride-rich lipoproteins is what drives the results in these studies and that is the reason why once you adjust for the cholesterol inside the lipoprotein, the risk is flattened.”

Prof Zambon presented a range of studies on the topic to illustrate his point and explained that the cause of ischaemic heart disease is not triglycerides by themselves, but “it is the cholesterol inside the triglyceride-rich lipoproteins that counts. That is why when you adjust for it, the effect of triglycerides is gone”.

‘Pears and apples’

He provided an overview of the results of studies on the genetics and pathophysiology of coronary heart disease, telling the conference: “Comparing triglyceride-rich lipoproteins and LDL is like comparing pears and apples, but they share one common feature – each of these lipoproteins contains one molecule of LDL.”

I believe there is plenty of evidence and robust data to suggest that triglycerides are the ‘Mr Hyde’ of lipoproteins, not the ‘Dr Jekyll’

Prof Zambon told the attendees: “I believe there is plenty of evidence and robust data to suggest that triglycerides are the ‘Mr Hyde’ of lipoproteins, not the ‘Dr Jekyll’. Raised triglyceride concentration is likely a marker of cholesterol – remember, we are always talking about how cholesterol carried in triglyceride-rich lipoproteins is indeed a causal risk factor for cardiovascular disease and keep in mind, one triglyceride-rich lipoprotein is as atherogenic for your arteries as one LDL.”

Prof Zambon concluded: “Available evidence suggests that the inflammatory components of the plaque in atherosclerosis are indeed modulated by the triglyceride-rich lipoproteins. I have shown that plaque regression seems to be greater when both LDL-C and TG plasma levels are controlled or at their goals and at near-optimal LDL-C levels, short- to medium-term risk of cardiovascular events remains high when triglycerides are high, particularly higher than 2 or 2.5mmol. There are studies showing that approaching, on top of LDL-C, using triglyceride-lowering agents effectively reduces cardiovascular risk in patients with elevated triglycerides.”

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]